AARDEX Group announces the opening of a new office in the U.S.

By establishing itself in the U.S., the Group aims to strengthen its business and maintain its position as market leader in digital adherence monitoring systems.

Joe Keenan will lead the business development for the pharma and biotech industry in North America.

With over 70% of AARDEX’s customers based in the U.S., this new office will support local existing customers and help grow the U.S. market. 

“Our team is very excited about this next step”, said David Dalla Vecchia, CEO of AARDEX Group. “Our digital adherence monitoring solution is designed to fit the rapidly evolving needs to speed-up drug development for the pharmaceutical and biotech companies”. 

Share This Post

You may also like...

Outsourcing in Clinical Trials Europe (1)
Breaking News

Meet us at Outsourcing in Clinical Trials Europe 2023

Exciting news! AARDEX Group is gearing up for one of the most highly anticipated events in the clinical trials industry – the 13th Annual Outsourcing in Clinical Trials Europe conference, which will take place in the beautiful city of Barcelona